微小管の脱ポリメリゼーションは,圧力過負荷による左心室縮症の犬における心筋収縮機能をin vivo正常化させます
M Koide1, M Hamawaki, T Narishige
1Gazes Cardiac Research Institute, Medical University of South Carolina, Charleston, SC 29403, USA.
Circulation
|August 30, 2000
まとめ
心臓細胞のマイクロチューブル密度の増加は,圧力過負荷の際に収縮機能障害に寄与する. コルキシンでマイクロチューブルをデポリマー化することで,実験的な大動脈狭窄症の犬の心臓機能が回復しました.
科学分野:
- 心血管生理学 心血管の生理学
- 細胞生物学 細胞生物学
- バイオケミストリー バイオケミストリー
背景:
- 心筋縮症は,心不全に進行する可能性があります.
- マイクロチューブルネットワークの密度の増加は,この移行のための提案されたメカニズムです.
- この細胞骨格の異常は,粘性負荷を課すことで心臓細胞の収縮を抑制する.
研究 の 目的:
- 心臓細胞の微小管ネットワーク密度の増加の役割を in vivoで調査する.
- この細胞骨格の異常が,実験的な大動脈狭窄における収縮機能障害に寄与するかどうかをテストする.
- 微小管のデポリメリゼーションによって心臓の機能を回復できるかどうかを判断する.
主な方法:
- 成犬における実験的な大動脈狭窄の誘導により,圧力過負荷が生じます.
- コルキシン投与前と後の左心室 (LV) 機能の測定.
- コルキシン治療前のおよび後の生検による心臓細胞の検査.
主要な成果:
- 重度のLV圧力過負荷と収縮機能不全の犬を研究した.
- コルチシンを静脈内投与すると,マイクロチューブルの脱ポリメリゼーションが起こります.
- 微小管のデポリメリゼーションにより,体内および体外の両方でLVの収縮機能が回復しました.
結論:
- 心臓細胞微小管ネットワークの密度の増加は,心室収縮機能不全の重要なメカニズムです.
- この機能不全は,成人期発症の圧力過負荷誘発性心筋縮症を有する大型哺乳類で発生する.
- マイクロチューブルネットワークをターゲットにすることで,心不全の治療の可能性が生まれます.
関連する概念動画
01:26Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
01:20Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
01:22Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...